Nikolay Houbenov

Title: **Nikolay Houbenov: Pioneering Advances in Pharmaceutical Crystallization**

Introduction

Nikolay Houbenov, an accomplished inventor located in Helsinki, Finland, has made significant contributions to the field of pharmaceuticals. His innovative approach to the crystallization of active pharmaceutical ingredients (APIs) has garnered attention in the industry, showcasing his expertise and dedication to scientific advancement.

Latest Patents

Nikolay Houbenov holds a notable patent titled "Method for crystallization of active pharmaceutical ingredients." This patent discloses methods for controlling the crystallization and crystal growth of APIs. The technique involves contacting solid amorphous nanosized API with an aqueous solution containing one or more polymers and/or copolymers, resulting in the formation of a suspension that contains nanosized API in crystalline form. This innovation stands to enhance the efficacy and quality of pharmaceutical formulations.

Career Highlights

Currently, Nikolay is employed at Nanoform Finland Oyj, a company that focuses on transforming the formulation of medicines through advanced nanotechnology. His role at Nanoform showcases his commitment to pushing the boundaries of pharmaceutical science. With a strong focus on developing scalable solutions, Nikolay's work is instrumental in improving drug delivery systems.

Collaborations

Throughout his career, Nikolay has worked alongside notable colleagues, including Martti Kaasalainen and Tatiana Danilova. Their collaborative efforts contribute significantly to the research and development initiatives at Nanoform, fostering an innovative environment that promotes groundbreaking advancements in pharmaceutical technologies.

Conclusion

Nikolay Houbenov's contributions to the field of crystallization techniques for active pharmaceutical ingredients underscore his role as a leading inventor in the pharmaceutical industry. His patent demonstrates a commitment to innovation and collaboration that continues to impact the future of drug development. As the pharmaceutical landscape evolves, Nikolay's work at Nanoform Finland Oyj is expected to drive further advancements, ensuring the continued progress of medication efficacy and safety.